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Introduction: Patients with non-small cell lung cancer (NSCLC) 
harboring anaplastic lymphoma kinase (ALK) rearrangement selec-
tively respond to ALK inhibitors. Thus, identification of ALK rear-
rangements has become a standard diagnostic test in advanced 
NSCLC patients. Our institution has been a referral center in Spain 
for ALK determination by Fluorescent in situ hybridization (FISH). 
The aim of our study was to assess the feasibility and the FISH pat-
terns of the ALK gene and to evaluate the clinical and pathological 
features of patients with ALK alterations. 
Methods: Between 2010 and 2014, 1092 samples were evaluated for 
ALK using FISH technique (927 histological samples, 165 cytologi-
cal samples). Correlation with available clinical-pathological infor-
mation was assessed.
Results: ALK rearrangement was found in 35 patients (3.2%). 
Cytological samples (using either direct smears or cell blocks), were 
more frequently non-assessable than histological samples (69% ver-
sus 89%, respectively) (p < 0.001). Within the ALK-rearranged cases 
the majority were female, non-smokers, and stage IV. 
Conclusions: Although assessable in cytological samples, biopsies are 
preferred when available for ALK evaluation by FISH. The ALK trans-
location prevalence and the associated clinico-pathological features in 
Spanish NSCLC patients are similar to those previously reported.
Key Words: ALK, FISH, Non-small cell lung cancer, Biopsy, 
Cytology.
(J Thorac Oncol. 2014;9: 1816–1820)
Lung cancer remains the leading cause of cancer related deaths in western countries.1 Over the last decade there 
have been important advances in understanding the biology of 
non-small cell lung cancer (NSCLC), by the identification of 
oncogene-driven subtypes of tumors.2–4
In 2007 Soda et al.5 identified a new oncogene in NSCLC, 
a fusion gene resulting from the paracentric inversion of the 
short arm of chromosome 2 fusing the anaplastic lymphoma 
kinase (ALK) gene, at 2p23 and the echinoderm microtubule-
associated protein-like 4 (EML4) gene at 2p21. EML4-ALK is 
an aberrant fusion gene that encodes a cytoplasmic chimerical 
protein with a constitutive tyrosine kinase activity and subse-
quently several downstream signaling pathways.6
Since then, several variants of the rearranged gene and 
different ALK partners such as KIF5B at 10p11.22,7 TFG 
at 3q12.2,8 HIP1 at 7q11.239 and TPR at 1q2510 have been 
identified. Moreover, oncogenic properties have also been 
described for atypical rearrangements with 5’ALK deletion 
with unknown partners.11
ALK rearrangement is found in 3 to 5% of all 
NSCLCs.11 In 2011 the FDA approved the use of crizotinib 
(Xalkori®, Pfizer), an oral ATP-competitive selective inhibi-
tor of the ALK and c-MET tyrosine kinase, with the encour-
aging results from a phase I trial with an overall response rate 
(ORR) of 60.8% and a progression free survival (PFS) of 9.7 
months.12 Moreover, recent phase I and II studies with new 
generation ALK tyrosine kinase inhibitors show promising 
response rates in patients with progression or naïve to crizo-
tinib. Globally, these efficacy results have prompted detection 
of ALK rearrangements as a routine test in every newly diag-
nosed NSCLC patient.
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A variety of methods are available to test for the ALK 
rearrangement including FISH (fluorescence in situ hybrid-
ization), IHC (immunohistochemistry), and RT-PCR (reverse 
transcriptase polymerase chain reaction). Currently, fluores-
cence in-situ hybridization (FISH) using break-apart probes 
remains the gold standard method for screening ALK rear-
rangements in lung clinical trials13 but the assay can be techni-
cally challenging. FISH technique relies mostly on the tumor 
sample quality, enough tumor cell representation and exper-
tise in the assessment.
Here we present data on the experience in ALK rear-
rangement detection by FISH in over 1000 samples in a single 
referral center with routine diagnostic specimens (biopsies 
and cytological samples).
MATERIAL AND METHODS
Samples
Our institution was appointed as a referral center 
in Spain for ALK rearrangement detection. A total of 1092 
NSCLC samples referred from 69 Spanish hospitals were 
examined between 2010 and 2014. Samples were received as 
paraffin-embedded (FFPE) biopsies or cytological specimens 
as stained smears or cell blocks. We requested paraffin blocks 
to be sent to our center, then 3–4microm section were cut for 
FISH testing according to our protocol. Adequacy of samples 
for ALK testing was reviewed by the referring pathologists but 
histology was not reviewed centrally.
ALK FISH
ALK FISH was conducted on formalin-fixed and paraf-
fin-embedded (FFPE) tissue as previously described14 using a 
commercially available dual-color break-apart probe specific 
to the ALK locus (Abbott Molecular Inc, Des Plaines IL,) 
according to manufacturer’s instructions. Fifty non-overlap-
ping cells with hybridization signals were examined for each 
case with a fluorescence microscope (Olympus, Barcelona, 
Spain) with the Cytovysion software (Applied Imaging, 
Santa Clara, CA). Samples were considered positive if more 
than 15% of cells showed split ALK 5' and 3' probe signals or 
isolated 3' signals. Isolated 5' signals are considered as nega-
tive. The distance between two separated signals was esti-
mated using twice the size of the biggest signal size. The use 
of break apart probes does not allow distinguishing between 
an inversion or translocation, without performing additional 
techniques. Thus we have used hereon the term translocation 
for simplicity. ALK copy number gains (CNG) and amplifica-
tions were classified following the criteria adopted by Salido 
et al.11 We considered that the FISH test had failed when the 
sample was not assessable. There are numerous preanalyti-
cal factors affecting the outcome of FISH on FFPE tissue: 
heterogeneous fixation conditions, age of the section degree 
of fibrosis, the use of mercurial solutions to decalcify bone 
biopsies, among others. Also, the most important process in 
FFPE FISH protocol is the pretreatment and consequently 
the protease digest times should be tailored for each indi-
vidual sample.
Clinical and Pathological Information
We retrospectively collected into a database the clini-
copathological characteristics of the external and in-house 
samples tested. Referring physicians were asked to fill in 
an on-line/paper form with clinicopathological queries. The 
series included samples from our institution, from which we 
had complete clinical information. Data were obtained from 
60% of the patients.
Statistical Analysis
Statistical associations were assessed using Pearson’s χ2 
test or Fisher’ exact test. All statistical tests were conducted 
at the two-sided 0.05 alpha level of significance. Statistical 
analysis was carried out with SPSS version 18 (SPSS Inc, 
Chicago, IL).
RESULTS
ALK Assessment
From the 1092 samples, 927 (85%) were biopsy speci-
mens (including surgical samples) and 165 (15%) cytological 
samples. Among them 827 biopsy samples (89.2%) and 114 
cytological specimens (69.1%) could be tested by FISH. In the 
other 153 (14%) cases, a FISH result was not obtained due to 
insufficient tumor material (n = 58) or assay failure (n = 95). 
We observed a significant association (p < 0.0001) between 
the type of sample tested and the ability to succeed in the 
FISH evaluation (89.2% biopsies versus 69.1% cytologies).
Within the 394 samples with complete information, 330 
(89%) were obtained from the lung primary tumor.
ALK Rearrangement
ALK FISH patterns are illustrated in Figure 1. ALK rear-
rangement was found in 35 cases (3.2%). From ALK positive 
cases, 23 (66%) showed a typical translocation pattern and 12 
(34%) an atypical translocation pattern with isolated 3'ALK sig-
nals (Fig. 2). The mean percentage of positive cells was 61% 
(range: 21–99%). The coexistence of copy number gains with 
both patterns of ALK rearrangements was frequent (69%). One 
case presented an atypical FISH pattern showing an extra 5'ALK 
signal. It has been reported that a patient with multiple single 
copies of the 5' ALK signal plus additional 5' doublets combined 
with 3' signal (suggesting a complex rearrangement) responded 
to ALK inhibition.15 This is different from our case that pre-
sented 86% of the nucleus with an isolated extra green signal 
without detection of 3' signals, so we considered it negative.
ALK Copy Number Changes
Copy number gains (CNG) were observed in up to 710 
cases (65%). In the majority of them, gains were seen in a high 
proportion of cells (ranging from 40% to 95%) (Fig. 2). FISH 
analysis identified 43 cases (3.9%) with ALK amplification in 
less than 10% of cells, 21 of them presented ALK signal clus-
ters and 22 had six or more ALK gene copies per cell. The per-
centage of amplified cells ranged between 15% and 60% and 
in all 43 amplified cases, CNG was observed (ranging from 
30% to 85%). In addition, nine cases (0.8%) had one ALK 
gene copy per cell, suggesting a monosomy of chromosome 2.
1818 Copyright © 2014 by the International Association for the Study of Lung Cancer
Vidal et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 12, December 2014
Association with Clinicopathological 
Information
Patient’s characteristics are summarized in Table 1. 
Among the 1092 patients tested for ALK, the majority were 
male (69%), with advanced stage at diagnosis (54.5%). The 
majority (75%) had history of smoking, either current or for-
mer, with a median cumulative index of 52 packs/year. The 
predominant histology was adenocarcinoma (79.6%), with a 
limited representation of other histological subtypes: squa-
mous cell carcinoma (SCC) in 5.7%, large cell carcinoma 
(LCC) in 5.8% and not otherwise specified (NOS) in 7.6%.
Clinicopathological differences between ALK-positive 
and ALK-negative patients are shown in Table 2. We observed a 
significant association between ALK translocation and female 
sex (p < 0.001), non-smoking history (p < 0.001) and advanced 
stage (p = 0.004). No differences were observed by histology 
although non-ADC samples were scarce. Among ALK posi-
tive patients, the majority were ADC (n = 28) although it is 
worth mention that two positive cases were detected in LCC. 
Within adenocarcinoma samples, information on growth pat-
tern was not available. No concomitant EGFR mutations were 
found in our series.
ALK amplification was not associated with any particu-
lar clinicopathological pattern. Two out of 43 cases with ALK 
amplification presented also an EGFR mutation detected in 
the diagnostic biopsy. One of them was treated with surgery 
alone and the other was a stage IV adenocarcinoma with a 
mutation in exon 18 who responded to gefitinib for 6 months 
before progression. The implication of ALK amplification in 
EGFR mutant cases remains unknown.
DISCUSSION
ALK assessment has become a routine test in patients 
with advanced NSCLC. Here we present the largest cohort 
of Spanish cases evaluated by FISH in a single institution. 
We have observed different FISH positivity patterns and evi-
denced the real limitations of cytological samples for ALK 
testing in routine clinical practice.16
We confirm the low frequency of ALK rearrangements 
(3%) in Caucasian population, and its association with female 
gender, non-smoking habit, and advanced stage.
FISH using ALK break-apart probe is considered the 
gold standard method for screening ALK-rearrangements, 
but results depend on preanalytical and analytical factors that 
may affect the quality of the specimen and the quantity of 
tumor cell representation.17 In our study, cytological samples 
3’orange and 5’green signal are overlapped or 
separated by less than twice the size of an 
isolated signal.
Negative
3’orange and 5’green signal are separated by 
more than twice the size of an isolated signal. Positive
Single 5’green signal without a corresponding 
3’orange signal, along with a fusion signal, 
indicates loss of 3’orange fragment.
Negative
Single 3’orange signal without a corresponding 
5’green signal, along with a fusion signal, 
indicates loss of 5’green fragment.
Positive
Same nuclei with several fusion signals and/or 
separated signals. 
Negative
Positive
Nuclei with one isolated signal. Uninformative
FIGURE 1.  Schematic diagram of the different cellular 
positive (split or single red) and negative (fused or single 
green) patterns for ALK status testing with fluorescence in situ 
hybridization.
A B
C D
FIGURE 2.  Four tumors samples exhibit-
ing different ALK break-apart FISH signal 
patterns. A, ALK negative polysomic nuclei 
showing between five and nine fused signals 
per cell. B, ALK negative amplification nuclei 
(arrow) showing clusters of fused signals. 
C, ALK positive nuclei showing split signals 
(arrows) and fused signal gains. D, ALK 
positive nuclei showing isolated single red 
signals (arrows).
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(using either direct smears or cell blocks), had lower rate of 
successful evaluation than histological samples (69% versus 
89%, respectively) (p < 0.001). The main reasons for assay 
failure were different fixation conditions in biopsies whereas 
in cytological smears it could be attributable to the duration of 
the archival (age of the section) or prior Papanicolaou stain-
ing. Although technical limitations were more frequently 
observed in cytological specimens, the percentage of inade-
quate or insufficient cases in our study was slightly lower than 
reported in other series including cytological smears.2 This 
type of samples should be reserved solely when material from 
small biopsies or cytological cell blocks are not available. In 
cases with high probability of ALK translocation (young age, 
no smoking history or adenocarcinoma histology with signet-
ring cells) it would be advisable to obtain additional samples 
if the cytology ALK report has been not assessable or unclear. 
This stresses the relevance of reviewing the sample that is 
being assessed before performing FISH to select the tumor 
areas and to ensure that there is enough material for adequate 
FISH analysis.
Regarding FISH patterns in ALK positive patients, simi-
larly to previously reported,18 the majority of patients showed 
a typical pattern of rearrangement and less frequently an 
atypical pattern with 5'ALK deletion. As expected, CNG was a 
frequent event as previously reported by our group11 probably 
reflecting a wide-genomic instability.
Several clinicopathological patterns have been asso-
ciated to ALK positivity such as young age, light smoking 
habit and adenocarcinoma histology, enriching the chances 
of positivity up to 35% following those criteria.19 As previ-
ously reported, our study observed a higher incidence of ALK 
rearrangements in adenocarcinomas and light or never smok-
ers. However, in our series, ALK rearrangements were more 
common in female patients. Initial reports described an asso-
ciation of ALK rearrangements with male gender20 but recent 
data from prospective clinical trials with crizotinib suggest no 
association with gender. In agreement with our results, there 
is a recent large population-based study performed in France, 
which describes a higher incidence in females,21 suggesting a 
real association in Caucasian population.
One of the limitations of our study is the lack of ALK 
immunohistochemical information about the samples ana-
lyzed. Being a large-scale study, we had to select one from 
both methods due to funding restrictions. FISH was cho-
sen due to the expertise of our cytogenetics department and 
because FISH was the gold standard technique in clinical tri-
als at the time of study initiation. There is increasing evidence 
suggesting a relatively high discordance rate between both 
techniques,21 so our data may underestimate the prevalence 
of ALK activated tumors in the studied population. From the 
data we have so far,21–23 we believe that positive cases obtained 
by either technique even though negative by a complimentary 
TABLE 1.  Demographic and Clinical-Pathological Patient’s 
Characteristics
Characteristics Total Cases
N 1092
Age 62.48
Gender
 Male 713 (68.9%)
 Female 322 (31.1%)
 Unknown 57
Smoking habit
 Never 167 (24.9%)
 Smoker 505 (75.1%)
 Unknown 420
Histology
 ADC 859 (79.6%)
 SSC 61 (5.7%)
 LCC 63 (5.8%)
 NOS 82 (7.6%)
 Others 14 (1.3%)
 Unknown 13
Stage
 I-III 305 (45.5%)
 IV 365 (54.5%)
 Unknown 422
ADC, adenocarcinoma; SSC, squamous cell carcinoma; LCC, large cell carcinoma; 
NOS, carcinoma not otherwise specified
TABLE 2.  Clinical-Pathological Differences Between ALK 
Positive and Negative Patients
Characteristics ALK-Negative ALK-Positive p
N 1057 35
Age 62.48 61 0.581
Gender
 Male 604 13 <0.001
 Female 260 19
 Unknown 3
Smoking habit
 Never 140 16 <0.001
 Smoker 451 10
 Unknown 9
Histology
 ADC 730 28 0.388
 SSC 55 0
 LCC 47 2
 NOS 58 1
 Others 12 1
 Unknown 3
Stage
 I-III 308 5 0.004
 IV 282 21
 Unknown 9
EGFR
 Wild type 306 6 1
 Mutated 29 0
 Unknown 29
ADC, adenocarcinoma; SSC, squamous cell carcinoma LCC, large cell carcinoma; 
NOS, carcinoma not otherwise specified; EGFR, endotelial growing factor receptor
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test, should be challenged with an ALK inhibitor, recommend-
ing an early assessment to rule out the possibility of a false 
negative determination.
In summary, ALK translocations incidence in Spanish 
population (3%) is in the same average than the reported in 
Caucasian population and seem to be more frequent in patients 
with light smoking history and female gender. Although 
assessable in cytological samples, biopsies are preferred for 
ALK evaluation by FISH in routine clinical practice.
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